Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relfydess for masseter muscle hypertrophy
ACTRN12625001280493Phase 4Not yet recruiting
- Sponsor
- Aesthetic Maxillofacial Clinic
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of relugolix + estradiol + norethindrone in masseter hypertrophy and bruxism (2 arms), sponsored by Aesthetic Maxillofacial Clinic. Primary endpoints: Responder rate by investigator assessment and Responder rate by participant assessment. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
relugolix + estradiol + norethindrone
03
Conditions
masseter hypertrophybruxism
Beyond the preview
Go deeper on ACTRN12625001280493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001280493.